Dolby Laboratories Files 8-K
Ticker: DLB · Form: 8-K · Filed: Aug 19, 2024 · CIK: 1308547
| Field | Detail |
|---|---|
| Company | Dolby Laboratories, INC. (DLB) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $429,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
Related Tickers: DLB
TL;DR
Dolby filed a standard 8-K, no major news.
AI Summary
Dolby Laboratories, Inc. filed an 8-K on August 19, 2024, to report other events and financial statements. The filing does not contain specific details about new events, acquisitions, or financial results beyond the standard reporting requirements.
Why It Matters
This filing indicates Dolby Laboratories is fulfilling its reporting obligations with the SEC, but it does not disclose new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine SEC disclosure and does not contain any new material information that would suggest increased risk.
Key Players & Entities
- Dolby Laboratories, Inc. (company) — Registrant
- August 19, 2024 (date) — Date of earliest event reported
- 1275 Market Street San Francisco , CA 94103-1410 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Dolby Laboratories, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as required by the SEC.
On what date was this 8-K report filed?
This 8-K report was filed on August 19, 2024.
What is Dolby Laboratories, Inc.'s principal executive office address?
Dolby Laboratories, Inc.'s principal executive office is located at 1275 Market Street, San Francisco, CA 94103-1410.
What is the Commission File Number for Dolby Laboratories, Inc.?
The Commission File Number for Dolby Laboratories, Inc. is 001-32431.
Does this filing disclose any new material events or financial results?
Based on the provided text, this filing appears to be a routine disclosure and does not specify any new material events or detailed financial results beyond the standard reporting categories.
Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-08-19 17:00:59
Key Financial Figures
- $0.001 — which registered Class A common stock, $0.001 par value DLB The New York Stock Ex
- $429,000,000 — for an aggregate cash purchase price of $429,000,000, subject to certain purchase price adju
Filing Documents
- d808465d8k.htm (8-K) — 24KB
- 0001193125-24-202859.txt ( ) — 139KB
- dlb-20240819.xsd (EX-101.SCH) — 3KB
- dlb-20240819_lab.xml (EX-101.LAB) — 17KB
- dlb-20240819_pre.xml (EX-101.PRE) — 11KB
- d808465d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DOLBY LABORATORIES, INC. By: /s/ A NDY S HERMAN Andy Sherman Executive Vice President, General Counsel, and Corporate Secretary Date: August 19, 2024